Clinical Trial Update: A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II study of BY101298, an oral DNA-PK inhibitor, in combination with radiotherapy for malignant solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• BY101298

Snippet

Sponsor: Chengdu Baiyu Pharmaceutical Co., Ltd. | Conditions: Solid Tumor, Adult | Phase 1, Phase 2 | Status: TERMINATED